SCHEDULE 13G/A: BlackRock Amends Stake in Fate Therapeutics, Disclosing 6.9% Ownership

BlackRock, Inc. has filed an Amendment No. 7 to Schedule 13G, reporting a 6.9% beneficial ownership stake in Fate Therapeutics Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 7 to Schedule 13G regarding its ownership in FATE THERAPEUTICS INC.
• As of March 31, 2025, BlackRock, Inc. beneficially owned an aggregate of 7,852,183 shares of Common Stock of FATE THERAPEUTICS INC.
• This represents 6.9% of the class of securities.
• BlackRock holds sole voting power over 7,725,394 shares and sole dispositive power over 7,852,183 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Several BlackRock subsidiaries, including BlackRock Institutional Trust Company, National Association and BlackRock Financial Management, Inc., may beneficially own shares, with some potentially owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as a major institutional investor like BlackRock maintaining a significant stake (6.9%) in a company generally signals confidence, especially when stated to be for ordinary course of business and not for control. There are no negative indicators in the filing.

Positives

• BlackRock, a major institutional investor, maintains a significant stake of 6.9% in Fate Therapeutics, indicating continued confidence in the company.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of influencing control, suggesting a passive investment stance.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Fate Therapeutics Inc.'s future outlook.

Management Comments

• The filing includes a certification from BlackRock, Inc. stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing reflects a routine disclosure by a major asset manager, BlackRock, regarding its passive investment in a biotechnology company, Fate Therapeutics. Such disclosures are common for large institutional investors holding significant stakes in publicly traded companies across various industries, including the highly innovative and capital-intensive biotechnology sector.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a regulatory disclosure of beneficial ownership by a large institutional investor. It does not provide operational or financial results for Fate Therapeutics Inc. that would allow for a direct comparison to industry-specific benchmarks or competitor performance.
• The 6.9% stake held by BlackRock is a substantial passive investment, typical for large asset managers in companies they deem attractive within their investment mandates.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially reinforcing investor confidence due to BlackRock's continued passive investment.
• Management: Confirms a stable, passive institutional shareholder base, which can be beneficial for long-term strategic planning without immediate pressure for control changes.

Next Steps

• BlackRock, Inc. will continue to file amendments to Schedule 13G if there are material changes to its beneficial ownership of Fate Therapeutics Inc. common stock.

Key Dates

Keywords

Fate Therapeutics, BlackRock, Schedule 13G, Common Stock, Institutional Ownership, Biotechnology, Pharmaceuticals, SEC Filing, Investment Management